Phase 1-2 multi-center study of intravenous BCX-1777 [forodesine] in patients with refractory cutaneous T-cell lymphoma

Trial Profile

Phase 1-2 multi-center study of intravenous BCX-1777 [forodesine] in patients with refractory cutaneous T-cell lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2013

At a glance

  • Drugs Forodesine (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 06 Dec 2007 Interim results will be presented at ASH in December 2007.
    • 18 Jan 2007 Interim results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top